Pancreatic Cancer Research

ResearcherUniversity of LouisvilleActive in the last 2 years

Lacey R. McNally

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6756-129X; OpenAlex author ID A5045193979; NIH RePORTER profile ID 8230129. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 11)
Trials
0
Grants
4
Labs led
4
Collaborators
32
Papers, trials and grants by year

2013: 1 paper, 1 grant · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 1 grant · 2020: 1 paper · 2021: 4 papers, 1 grant · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers, 1 grant · 2026: 2 papers

Papers 17

  1. Correction to "Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer". Last author DOI 10.1021/acsami.6c01352↗
  2. Peptide-Based Probe Targeting Angiotensin Type‑1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography. Last author DOI 10.1021/cbmi.5c00128↗
  3. pH-Responsive Liposomes for Targeted Detection of Pancreatic Adenocarcinoma Using MSOT. Last author DOI 10.1021/cbmi.5c00034↗
  4. RETRACTED: Thomas et al. Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Cancers 20… Last author DOI 10.3390/cancers17243888↗
  5. Theranostic nanoparticles for detection and treatment of pancreatic cancer. Last author DOI 10.1002/wnan.1983↗
  6. Innovative Imaging Techniques Used to Evaluate Borderline-Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jss.2022.10.008↗
  7. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103271↗
  8. Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. Last author DOI 10.1021/acsami.1c09379↗
  9. Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. Co-author DOI 10.1038/s41598-021-83658-3↗
  10. Treatment and Visualization of Pancreatic Ductal Adenocarcinoma through Actively Targeted Copper 64 Nanoparticles. First author DOI 10.1148/rycan.2021219005↗
  11. RETRACTED: Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Last author DOI 10.3390/cancers12082279↗
  12. Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo. Last author DOI 10.1158/1078-0432.ccr-15-0314↗
  13. Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography. Last author DOI 10.1186/s12951-015-0139-8↗
  14. Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography. Last author DOI 10.1158/0008-5472.can-14-1656↗
  15. Fusion of cell-penetrating peptides to thermally responsive biopolymer improves tumor accumulation of p21 peptide in a mouse model of pancreatic cancer. Co-author DOI 10.2147/dddt.s60451↗
  16. Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy. Last author DOI 10.6092/1590-8577/1900↗
  17. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. Co-author DOI 10.1371/journal.pcbi.1003231↗

Grants 4

  1. Development of contrast agents to facilitate image-guided surgery R01CA281098↗
  2. Stroma Targeted Theranostic Nanoparticles for Pancreatic Cancer R01CA212350↗
  3. Theranostic Nanoparticles For Detection and Treatment of Pancreatic Cancer R01EB020125↗
  4. KiSS1 treatment of pancreatic adenocarcinoma R00CA139050↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ajay Jain · 3 shared papers, 1 shared grant, 2023–2025 · strength 1.70
  2. William M. MacCuaig · 7 shared papers, 2020–2026 · strength 1.31
  3. Barish H. Edil · 5 shared papers, 2020–2026 · strength 0.97
  4. Rohit Singh · 3 shared papers, 2024–2026 · strength 0.75
  5. Happy Agarwal · 3 shared papers, 2024–2026 · strength 0.75
  6. Priyabrata Mukherjee · 3 shared papers, 2021–2026 · strength 0.54
  7. Wenyuan Yin · 5 shared papers, 2014–2025 · strength 0.46
  8. Isabel S. Dennahy · 2 shared papers, 2023–2024 · strength 0.36
  9. Alexandra Thomas · 2 shared papers, 2020–2025 · strength 0.31
  10. Michael E. Egger · 2 shared papers, 2020–2025 · strength 0.31
  11. Susanna Varkey Ulahannan · 1 shared paper, 2026 · strength 0.30
  12. Morgan Bonds · 1 shared paper, 2023 · strength 0.18
  13. Hunter Chalfant · 1 shared paper, 2023 · strength 0.18
  14. Hermann B. Frieboes · 3 shared papers, 2013–2014 · strength 0.15
  15. Maged Henary · 1 shared paper, 2021 · strength 0.13
  16. Matthew D. Laramie · 1 shared paper, 2021 · strength 0.13
  17. Xiaoping Li · 1 shared paper, 2021 · strength 0.11
  18. Min Li · 1 shared paper, 2021 · strength 0.11
  19. Xiuhui Shi · 1 shared paper, 2021 · strength 0.11
  20. Zhijun Zhou · 1 shared paper, 2021 · strength 0.11
  21. Jingxuan Yang · 1 shared paper, 2021 · strength 0.11
  22. Mingyang Liu · 1 shared paper, 2021 · strength 0.11
  23. Courtney W. Houchen · 1 shared paper, 2021 · strength 0.11
  24. Hanxiang Zhan · 1 shared paper, 2021 · strength 0.11
  25. Charles W. Kimbrough · 2 shared papers, 2015 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.